We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Lithocholic Acid Kills Cancer, Spares Healthy Cells

By LabMedica International staff writers
Posted on 19 Jan 2012
Print article
Lithocholic acid (LCA), naturally generated in the liver during digestion, has been seriously underestimated because new research has revealed that LCA can kill several kinds of cancer cells, such as those found in breast cancer and various brain tumors.

The researchers, led by Concordia University (Austin, TX, USA), included scientists from McGill University (Montreal, Canada) and the Jewish General Hospital’s Lady Davis Institute (Montreal, Canada), as well as the University of Saskatchewan (Saskatoon, Canada). The study’s findings were published October 2011 in the journal Oncotarget.

Earlier research from the same investigators demonstrated LCA also extends the lifespan of aging yeast. This time, the team found LCA to be very selective in killing cancer cells while leaving normal cells unscathed. This could translate into a great improvement over the indiscriminant all-cell damaging drugs used in chemotherapy.

“LCA doesn’t just kill individual cancer cells. It could also prevent the entire tumor from growing,” stated senior author Vladimir Titorenko, a professor in the department of biology and Concordia University research chair in genomics, cell biology, and aging.

Moreover, LCA prevents tumors from releasing substances that cause neighboring cancer cells to grow and proliferate. Prof. Titorenko noted that LCA is the only compound that targets cancer cells, which could translate into tumor-halting power. “This is important for preventing cancer cells from spreading to other parts of the body,” he said, noting that unlike other antiaging compounds, LCA blocks cancer cell growth yet lets normal cells continue to grow.

The next phase for the research team will be to test LCA’s effect on different cancers in mice models. Prof. Titorenko expects that LCA will also kill cancer cells in the research and lead to human clinical trials. “Our study found that LCA kills not only tumors [neuroblastomas], but also human breast cancer cells,” said Prof. Titorenko. “This shows that it has a wide effect on different types of cancers.”

Prof. Titorenko emphasized that dissimilar to agent utilized in chemotherapy, LCA is a natural compound that is already present in humans. Studies have shown that LCA can be safely given to mice by adding it to their food. Therefore, scientists are looking into why LCA is so lethal for cancer cells. Prof. Titorenko conjectures that cancer cells have more sensors for LCA, which makes them more sensitive to the compound than normal cells.

LCA sensors transmit signals to mitochondria. It seems that when these signals are too strong, mitochondria self-destruct and take the cell along with them. Simply stated, Prof. Titorenko and his colleagues engaged in cancer cell disruption by targeting a weakness to LCA.

Related Links:
Concordia University
McGill University
Jewish General Hospital’s Lady Davis Institute


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.